aTYR PHARMA INC
ATYR evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $29.9M
What it means
What to watch
Prepared research question
What matters most for ATYR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATYR
aTYR PHARMA INC (ATYR) is a clinical-stage biotechnology company developing first-in-class therapies for fibrosis and inflammation based on its proprietary tRNA synthetase platform, with lead candidate efzofitimod advancing toward Phase 3 trials in pulmonary sarcoidosis.
Key risk: Cash runway limited
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$29.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
aTYR PHARMA INC (ATYR) is a clinical-stage biotechnology company developing first-in-class therapies for fibrosis and inflammation based on its proprietary tRNA synthetase platform, with lead candidate efzofitimod advancing toward Phase 3 trials in pulmonary sarcoidosis.
- Lead candidate efzofitimod has reached alignment with the FDA on the Phase 3 study protocol for pulmonary sarcoidosis, with study activities expected to begin in Q4 2026 [sec · filed 2026-09-24].
- As of June 30, 2026, the company reported cash & equivalents of $16.2M, net income of -$10.3M, and shareholders' equity of $48.8M [sec].
- The company completed enrollment in the Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD, with topline results expected in Q1 2027 [news · published 2026-08-07].
- aTyr has an accumulated deficit of $617.0 million as of March 31, 2026, and has not derived any revenue from product sales to date [sec_mda · as of 2026-05-15].
- In August 2026, the company announced a workforce reduction of approximately 60% and program prioritization to conserve capital and focus on the efzofitimod program [news · published 2026-08-07].
What works
- FDA alignment on the Phase 3 protocol for efzofitimod in pulmonary sarcoidosis provides a clear regulatory path forward [sec · filed 2026-09-24].
- The company has completed key manufacturing milestones, including three process performance qualification batches required for a potential BLA submission [sec · filed 2026-03-26].
- aTyr's proprietary tRNA synthetase platform has generated multiple preclinical candidates, including ATYR0101, which showed favorable pharmacokinetic and immunogenicity profiles in fibrosis models [sec · filed 2026-03-26].
What to weigh
- The company has no revenue from product sales and has an accumulated deficit of $617.0 million as of March 31, 2026 [sec_mda · as of 2026-05-15].
- Cash & equivalents stood at only $16.2M as of June 30, 2026, following a $58.9M cash position at the end of Q2 2026, indicating rapid cash burn [sec; news · published 2026-08-07].
- A 60% workforce reduction and program prioritization were announced in August 2026, reflecting financial constraints and a narrowed focus [news · published 2026-08-07].
- The company expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
FDA alignment on Phase 3 protocol for efzofitimod
“aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, symptomatic pulmonary sarcoidosis”
SEC filings · September 24, 2026
Workforce reduction and program prioritization
“Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD”
News · August 7, 2026
Cash position as of Q2 2026
“Ended the second quarter 2026 with $58.9 million in cash, cash e”
News · August 7, 2026
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash & equivalents of $16.2M as of June 30, 2026, with ongoing losses and no product revenue [sec].
- Dependence on single program — After restructuring, company is focused almost entirely on efzofitimod, increasing risk if Phase 3 fails [news · published 2026-08-07].
- Accumulated deficit growing — Accumulated deficit of $617.0M as of March 31, 2026, with net losses expected to continue [sec_mda · as of 2026-05-15].
- Phase 3 execution risk — Global Phase 3 study in pulmonary sarcoidosis is resource-intensive and depends on successful enrollment and endpoints [news · published 2026-09-24].
What to watch
- Initiation of Phase 3 study activities for efzofitimod in pulmonary sarcoidosis in Q4 2026 [news · published 2026-09-24].
- Topline results from the Phase 2 EFZO-CONNECT study in SSc-ILD expected in Q1 2027 [news · published 2026-08-07].
- Cash burn rate and any additional financing or partnership announcements given the limited cash position [sec].
- FDA feedback on the Phase 3 protocol for efzofitimod, expected by end of August 2026 [news · published 2026-08-07].
Sources: News · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run aTYR PHARMA INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available aTYR PHARMA INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.43 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Financials
Short Interest
as of May 20, 2026- % of float
- 23.3%
- Days to cover
- 22.0
- Shares short
- 19,845,053
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATYR short interestGovernance
Frequently asked questions
What is the AI investment thesis for aTYR PHARMA INC?
aTYR PHARMA INC (ATYR) is a clinical-stage biotechnology company developing first-in-class therapies for fibrosis and inflammation based on its proprietary tRNA synthetase platform, with lead candidate efzofitimod advancing toward Phase 3 trials in pulmonary sarcoidosis.
Who is the CEO of aTYR PHARMA INC?
Dr. Sanjay S. Shukla M.D., M.S. is the chief executive officer of aTYR PHARMA INC (ATYR).
Where is aTYR PHARMA INC headquartered?
aTYR PHARMA INC (ATYR) is headquartered in San Diego, CA, United States.
What therapeutic areas does aTYR PHARMA INC focus on?
aTYR PHARMA INC develops therapies across Respiratory, Nephrology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.